Bringing new concepts of functionalised nano particles for targeted delivery, SMi’s 7th annual RNA Therapeutics conference will feature a mix of case study-led presentations, panel debates, interactive workshops and keynote addresses tailored for an audience of professionals and research scientists looking to develop and commercialise novel RNA therapeutics and delivery systems.
With a focus on messenger RNA-based Therapeutics and anti-sense oligonucleotide-based drugs, the agenda will hone in on major developments and tackle the challenge of transporting RNA to target sites outside the liver and optimise bioavailability and kinetics.
Join us next February to expand your scientific horizons on topics such as ophthalmology injury, emerging concepts in delivery systems, oligonucleotides, aptamer-conjugates, messenger RNA therapeutics, plus much more!
Reasons to Attend:
-Learn new Pre-clinical and clinical developments with antisense oligonucleotide based delivery
-Rationalise the design criteria of multifunctional nanoparticle carriers
-Gain new insight of optimising mRNA therapeutics and delivery methods
-Understand industry hurdles of targeted delivery beyond the liver
-Discover new avenues in gene- based therapies
Key Speakers Include:
-Ryszard Kole, Distinguished Scientist, Sarepta Therapeutics
-Nagy Habib, Professor of Surgery, Chairman and Co-founder Imperial College London, MiNA Therapeutics
-Punit Seth, Executive Director, Isis Pharmaceuticals
-Mustafa Diken, Deputy Vice President, Immunotherapies and Preclinical Research, BioNTech AG
-Christian Schetter, Chief Executive Office and Managing Director, Rigontech GmbH
-Cristianne Rijcken, CSO, Cristal Therapeutics
-Heinrich Haas, Vice President RNA Formulation and Drug Delivery, BioNTech AG
-Brian Kelly, Associate, Covington and Burling LLP
With a focus on messenger RNA-based Therapeutics and anti-sense oligonucleotide-based drugs, the agenda will hone in on major developments and tackle the challenge of transporting RNA to target sites outside the liver and optimise bioavailability and kinetics.
Join us next February to expand your scientific horizons on topics such as ophthalmology injury, emerging concepts in delivery systems, oligonucleotides, aptamer-conjugates, messenger RNA therapeutics, plus much more!
Reasons to Attend:
-Learn new Pre-clinical and clinical developments with antisense oligonucleotide based delivery
-Rationalise the design criteria of multifunctional nanoparticle carriers
-Gain new insight of optimising mRNA therapeutics and delivery methods
-Understand industry hurdles of targeted delivery beyond the liver
-Discover new avenues in gene- based therapies
Key Speakers Include:
-Ryszard Kole, Distinguished Scientist, Sarepta Therapeutics
-Nagy Habib, Professor of Surgery, Chairman and Co-founder Imperial College London, MiNA Therapeutics
-Punit Seth, Executive Director, Isis Pharmaceuticals
-Mustafa Diken, Deputy Vice President, Immunotherapies and Preclinical Research, BioNTech AG
-Christian Schetter, Chief Executive Office and Managing Director, Rigontech GmbH
-Cristianne Rijcken, CSO, Cristal Therapeutics
-Heinrich Haas, Vice President RNA Formulation and Drug Delivery, BioNTech AG
-Brian Kelly, Associate, Covington and Burling LLP
